Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Presentation TCT 2024

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

Presenter: Bu-Yuan Hsiao

October 29, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2024

Shelley Wood

April 30, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Opinion Editor's Corner ACC 2024

What’s Going to Be Hot at ACC 2024

Shelley Wood

April 01, 2024

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2023

Shelley Wood

November 30, 2023

Presentation AHA 2023

Dapagliflozin in myocardial infarction without diabetes or heart failure

Presenter: Stefan James

November 14, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Todd Neale

July 17, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

Advertisement

What’s Going to Be Hot at ESC Congress 2025?

What’s Going to Be Hot at ACC 2025?

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

TCT 813: Long-Term Outcomes of Dapagliflozin in Acute Myocardial Infarction and Preserved Ejection Fraction

CMS Announces Negotiated Medicare Prices for First 10 Drugs

August 2024 Dispatch for the CV Team

TCTMD’s Top 10 Most Popular Stories for April 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

What’s Going to Be Hot at ACC 2024

Top Coronary Artery Disease News of 2023

TCTMD’s Top 10 Most Popular Stories for November 2023

Dapagliflozin in myocardial infarction without diabetes or heart failure

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

What’s Going to Be Hot at AHA 2023

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

The Biggest News of 2022: TCTMD’s Top 10

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content